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Abstract
Metabolic syndrome is associated with visceral obesity, insulin resistance and an increased risk of cardiovascular diseases.
Visceral fat tissue primarily consists of adipocytes that secrete cytokines leading to a state of systemic inflammation in obese
conditions. One of the IGF-independent functions of IGFBP-3 is its role as an anti-inflammatory molecule. Our study in obese
adolescents show a decrease in total IGFBP-3 levels and increase in proteolyzed IGFBP-3 in circulation when compared to
their normal counterparts and establishes a positive correlation between IGFBP-3 proteolysis and adiposity parameters as
well as insulin resistance. In human adipocytes, we show that IGFBP-3 inhibits TNF-a-induced NF-kB activity in an IGF-
independent manner, thereby restoring the deregulated insulin signaling and negating TNF-a-induced inhibition of glucose
uptake. IGFBP-3 further inhibits TNF-a, CRP and high glucose-induced NF-kB activity in human aortic endothelial cells
(HAECs) and subsequently suppresses monocyte adhesion to HAEC through the IGFBP-3 receptor. In conclusion, these
findings suggest that reduced levels of IGFBP-3 in circulation and reduced expression of IGFBP-3 in macrophages in obesity
may result in suppression of its anti-inflammatory functions and therefore IGFBP-3 may present itself as a therapeutic for
obesity-induced insulin resistance and for events occurring in the early stages of atherosclerosis.
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Introduction
Over the past two decades obesity has dramatically increased
resulting in one-third of the adults in the United States being obese
[1]. Obesity is a complex disorder and is a major risk factor
associated with the incidence of diabetes, insulin resistance,
cardiovascular diseases (CVD), hypertension, diabetic retinopathy
and other metabolic disorders [2]. The endocrine paradigm
suggests that visceral fat in obesity, consisting primarily of
adipocytes, secretes various pro-inflammatory and pro-atherogenic
adipokines such as TNF-a, C-reactive protein (CRP) [3], IL-6 and
others [4] creating a state of local inflammation further resulting in
chronic systemic inflammation and accelerating the events leading
to metabolic disorders.
The IGF system plays a major role in growth, development and
maintenance of homeostasis in normal cells. Insulin-like growth
factor binding protein-3 (IGFBP-3), the major binding protein in
circulation [5] has been shown to be associated with CVD,
coronary events [6] and thickness of the intima-media [7]. A study
comparing the concentrations of IGFs and IGFBP-3 with respect
to BMI and body fat revealed that these levels are decreased in
obese women [8]. IGFBP-3 overexpression in the retinal
endothelium has also been shown to restore vascular integrity,
suggesting that IGFBP-3 may represent treatment of diabetic
retinopathy [9]. These observations clearly indicate involvement of
IGFBP-3 in CVD, obesity and insulin resistance; however the
mechanisms responsible for the role of IGFBP-3 in metabolic
syndrome remains poorly understood.
In addition to IGF-dependent functions, IGF-independent
functions of IGFBP-3 have also been studied [10]. Some of the
disease states that show IGF-independent actions of IGFBP-3
include cancer [11] and asthma [12]. IGFBP-3 exerts antitumor
and anti-inflammatory effects via a specific receptor (IGFBP-3R)
that involves activation of caspase pathway and cross-talk with NF-
kB signaling [11,13]. Another interesting attribute that may
regulate the functions of IGFBP-3 is proteolytic cleavage of
IGFBP-3 that has been reported in several physiological and
pathological conditions, including cancer, type 1 and 2 diabetes,
burn injuries, and surgery, suggesting that catabolic states increase
degradation of circulating IGFBP-3 [14–18]. In line with the
potential anti-inflammatory role of IGFBP-3 in cancers and other
diseases [11–13,15,16] and its crosstalk with the NF-kB pathway,
our study investigates the relationship between proteolyzed
IGFBP-3 in circulation and the parameters of adiposity and the
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e55084
potential role of IGFBP-3 in obesity-induced insulin resistance and
its involvement in the progression of atherosclerosis and CVD.
Results
IGFBP-3 Profile in Normal and Obese Adolescents
A total of 197 adolescents aged 12 to 13 years were classified
into control, overweight and obese groups according to BMI for
age and gender. Comparisons of clinical features in all groups
(Table 1) show that the obese group had significantly higher
height, weight, BMI, waist circumference, systolic BP and diastolic
BP than controls. HDL-cholesterol levels were markedly decreased
in the obesity group. The obesity group had much higher levels of
triglycerides, LDL-cholesterol and ALT than the controls
(Table 2). Fasting insulin levels differed significantly in the obesity
compared with other groups. The levels of fasting glucose were
increased in the overweight and obesity compared to the control
but was not significantly different between each other. HOMA-IR
increased similarly (Table 3). Serum IGF-1 was increased in
overweight and obese individuals compared with the normal
group whereas total IGFBP-3 showed a slight increase in
overweight individuals. However both IGF-1 and total IGFBP-3
levels showed a significant decrease in obese individuals compared
to overweight individuals. Total IGFBP-3 levels in particular were
less even when compared to the normal group (Table 1). The data
further shows an increase in the IGF-1/IGFBP-3 in both
overweight and obese groups when compared to the control
group. In order to further analyze the IGFBP-3 levels, we
determined the presence and distribution of proteolyzed IGFBP-3
in the overweight and obese subjects by Western immunoblot
assay as well as protease activity assay. The western blot analysis of
the serum samples shows a robust presence of IGFBP-3 proteolytic
fragments (29-kDa and 18-kDa) in the obese and overweight
groups, but low or no detection of these fragments were seen in
controls. Densitometric analysis of the proteolytic IGFBP-3
fragments showed a 183 percent and a 184 percent increase in
the overweight and obese groups respectively when compared to
the control group (Figure 1A).
To investigate this further protease activity assay was performed
on the samples, in which recombinant human glycosylated
IGFBP-3 was biotinylated and IGFBP-3 protease activity was
measured as the ability of serum samples from control, overweight
and obese individuals to proteolyze biotinylated IGFBP-3. Results
show that IGFBP-3 protease activity increased in overweight and
obese individuals compared to the control group, but did not differ
between the overweight and obese groups (Figure 1B).
Further statistical analyses revealed that proteolyzed IGFBP-3
positively correlates with adiposity parameters such as waist
circumference (r = 0.608, P,0.001), BMI (r = 0.4651, P,0.001),
fasting insulin (r = 0.307, P = 0.001), and insulin resistance index
(HOMA-IR) (r = 0.313, P,0.001) in overweight and obese
population (Figure 1C), suggesting that predisposition to insulin
resistance and other consequences of increased visceral fat can
occur even in overweight individuals and not necessarily only in
obese population.
Taken together, based on our data and previous studies
demonstrating IGFBP-3 proteolysis in patients with type 2
diabetes [17], we speculate that increased proteolytic IGFBP-3
fragments in overweight and obese individuals probably result in
reduced levels of intact IGFBP-3 thereby inhibiting its IGF-
independent anti-inflammatory functions. Based on these findings,
we further investigated the effect of IGFBP-3 and its underlying
mechanism in cytokine-induced insulin resistance in adipocytes
and early manifestations of atherosclerosis in HAECs.
TNF-a Activates the NF-kB Pathway in Adipocytes in an in
vitro System
Visceral adipocytes are highly responsive to TNF-a mediated
activation of NF-kB pathway [18]. In order to confirm that the
NF-kB pathway was intact in fully differentiated human primary
adipocytes (ASCs), cells were treated with TNF-a and the pattern
of NF-kB activation was analyzed. Figure 2A clearly indicates the
cyclic phosphorylation pattern of IkBa and a time dependent
increase in the levels of phospho-NF-kBp65. These results indicate
that TNF-a activates the NF-kB pathway in ASCs.
Activation of the NF-kB Pathway Affects Insulin Signaling
in Adipocytes
Cytokines such as TNF-a, interferes with insulin signaling by
decreasing the levels of Insulin receptor substrate-1 (IRS-1) and
Glucose transporter-4 (GLUT4) [19,20]. Deficient levels of
adiponectin, an insulin sensitizing and anti-inflammatory adipo-
kine are observed in individuals with visceral fat [21]. Our
experiment was to determine the effect of TNF-a on IRS-1,
GLUT4 and adiponectin levels in in vitro ASCs. Figure 2B
demonstrates that TNF-a treatment decreases the transcriptional
levels of IRS-1, GLUT4 and adiponectin in a dose dependent
manner and treatment with IKK inhibitor shows that the reduced
mRNA levels of our genes of interest were restored, confirming
that TNF-a exerts its effect through the NF-kB pathway in
adipocytes. This was confirmed by the decrease in the protein
levels of IRS-1 with dose dependent TNF-a treatment (Figure 2C).
IGFBP-3 Inhibits the NF-kB Activity in Primary Human
Adipocytes
To investigate the anti-inflammatory function of IGFBP-3 on
TNF-a-induced NF-kB pathway and insulin signaling in ASCs,
TNF-a treated cells were infected with adenoviral constructs
containing IGFBP-3 sequence (Ad:IGFBP-3). ASCs produce no
detectable basal level of IGFBP-3 and TNF-a-treatment shows no
change in IGFBP-3 at the mRNA and protein levels (Figure 3).
TNF-a inhibits IRS-1, GLUT4 and adiponectin in TNF-a-treated
control cells, however, infection with Ad:IGFBP-3 restored IRS-1,
GLUT4 and adiponectin mRNA (Figure 3A) and protein levels
(Figure 3B). Overexpressed IGFBP-3 inhibits TNF-a-mediated
induction of MCP-1 at both mRNA (Figure 3A) and protein levels
(Figure 3B). Cells treated with IKK inhibitor confirmed in-
volvement of the NF-kB pathway. These data show that IGFBP-3
inhibits the TNF-a-induced NF-kB activity, thereby restoring
insulin signaling in ASCs.
IGFBP-3 Inhibits NF-kB Pathway in Human Adipocytes in
an IGF-independent Manner
In order to decipher if IGFBP-3 inhibits the NF-kB pathway in
adipocytes in an IGF- independent manner, we used IGFBP-3
GGG mutant, which has no binding affinity to IGF and therefore
any effect of this mutant would be an IGF independent effect [22].
On infection with Ad:EV, Ad:IGFBP-3 and Ad:IGFBP-3GGG
mutant, semi-quantitative PCR shows that the effect of
Ad:IGFBP-3GGG on the mRNA levels of GLUT4, IRS-1,
adiponectin and MCP-1 was similar to Ad:IGFBP-3 suggesting
that IGFBP-3 effect on the NF-kB pathway in adipocytes was IGF-
independent (Figure 3C). Protein expression of IRS-1, GLUT4,
adiponectin and MCP-1 confirmed that IGFBP-3 inhibits the NF-
kB pathway and successfully restores the repressed levels of IRS-1,
GLUT4 and adiponectin in ASCs in an IGF-independent manner
(Figure 3D).
Impact of IGFBP-3 in Human Metabolic Syndrome
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TNF-a Induces Insulin Resistance in Human Adipocytes
The dose dependent effect of insulin on increasing glucose
uptake in ASCs has been demonstrated in Figure 3E. However,
visceral obesity is accompanied by release of various adipokines
that leads to an inflammatory state resulting in insulin resistance
wherein cells cease to respond to insulin presence. Figure 3F shows
that increase in glucose uptake in the adipocytes on addition of
insulin is inhibited in the presence of TNF-a, showing its role in
insulin resistance. The IKK inhibitor treatment restores glucose
uptake by the cells indicating that the decrease in glucose uptake
by TNF-a was mediated via the NF-kB pathway.
IGFBP-3 Negates TNF-a Induced Inhibition of Glucose
Uptake in Human Adipocytes
In order to determine the effect of IGFBP-3 on TNF-a-induced
insulin resistance, adipocytes were infected with IGFBP-3 alone
and in the presence of TNF-a and insulin. Figure 3G shows that
insulin alone increased the glucose uptake to almost 400 percent,
however no change in glucose uptake was observed in the presence
of IGFBP-3 alone, suggesting that IGFBP-3 under normal
conditions does not regulate glucose metabolism. On the contrary,
cells treated with TNF-a and insulin together showed more than
a 50 percent decrease in glucose uptake but infection with IGFBP-
3 abolished the TNF-a effect and restored levels of glucose uptake.
Therefore, IGFBP-3 abrogates TNF-a-mediated inhibition of
glucose uptake in human adipocytes and does not affect normal
glucose metabolism.
TNF-a Activates the NF-kB Pathway in HAECs
In obesity, cytokines like TNF-a are elevated in circulation and
result in cardiovascular endothelial dysfunction, plaque formation
and CVD [23]. We studied the effect of TNF-a on cardiovascular
endothelial cells by treating HAECs with TNF-a and observed
a cyclic pattern in the levels of phospho-IkBa and total IkBa and
an increase in phospho-p65 levels (Figure 4A). Figure 4B, shows
that the downstream targets of the NF-kB pathway, ICAM-1,
VCAM-1 and MCP-1 mRNA levels increased in a dose de-
pendent manner ranging 0–100 ng/ml of TNF-a treatment and
Figure 4C shows a dose dependent increase in the protein
expression of ICAM-1 and VCAM-1 with TNF-a treatment.
Expression Pattern of IGFBPs in HAECs
Figure 4D shows detectable endogenous levels of IGFBP-
3 mRNA; however levels of other IGFBPs were not detected.
Furthermore, Figure 5E shows no detectable levels of IGFBP-3 at
the protein level and TNF-a treatment alone does not alter the
levels of IGFBP-3 protein secreted in the conditioned media.
IGFBP-3 Inhibits TNF-a Induced Activation of NF-kB
Activity in HAECs
To determine if IGFBP-3 also plays an anti-inflammatory role
in HAECs, TNF-a treated HAECs were infected with Ad:IGFBP-
3 and the mRNA and expression levels of NF-kB-regulated target
genes were analyzed. Figure 5A shows that IGFBP-3 alone has no
effect on the mRNA levels however, infection with Ad:IGFBP-3,
in the presence of TNF-a (50 ng/ml) significantly downregulates
the mRNA levels of TNF-a-induced ICAM-1, VCAM-1 and
MCP-1. IKK inhibitor treatment confirms that TNF-a and
IGFBP-3 mediate their effects by regulating the NF-kB pathway.
Figure 5B shows the protein profile for ICAM-1, confirming that
Figure 1. Increased IGFBP-3 proteolysis in obese adolescents. (A) The IGFBP-3 proteolytic fragments were detected by Western blot assay.
Optical density was significantly increased in the overweight and obesity. *, control vs. overweight, 2.0961.32 (100%) vs. 3.8360.37 (183%), P,0.001;
**, control vs. obesity, 2.0961.32 (100%) vs. 3.8560.63 (184%), P,0.001). (B) Protease activity assay was performed to determine IGFBP-3 proteolysis.
The activity was measured as optical density and it was significantly higher in the overweight and obese group. *, control vs. overweight,
0.66760.030 vs. 0.70760.038, P = 0.001; **, control vs. obesity, 0.66760.030 vs. 0.70860.043, P = 0.002). (C) Relationship between IGFBP-3 proteolysis
and (i) waist circumference (r = 0.707, P,0.0001), (ii) BMI (r = 0.759, P,0.0001), (iii) fasting insulin (r = 0.309, P,0.001), and (iv) HOMA-IR (r = 0.337,
P,0.001) were calculated by Pearson’s correlation coefficient.
doi:10.1371/journal.pone.0055084.g001
Table 1. Clinical and anthropometric characteristics of
subjects.
Controls Overweight Obese
P
value
n (M:F) 100 (49:51) 41 (19:22) 56 (25:31) NS
Age (years) 12.260.4 12.260.4 12.260.3 NS
Weight (kg) 47.266.9 61.066.9 69.767.7 a
Height (cm) 156.967.1 157.967.2 16065.7 b
BMI (kg/m 2) 19.161.9 24.461.0 27.261.8 a
Waist Circumference (cm) 68.566.2 80.865.6 87.967.0 a
Systolic BP (mmHg) 101.2610.8 107.9610.6 114.8610.7 a
Diastolic BP (mmHg) 63.666.4 65.667.5 69.967.8 c
IGF-1 (ng/ml) 120.3663.4 153.6688.1 145.5673.8 d
IGFBP-3 (ug/mL) 7.1161.16 7.4761.02 6.8261.28 e
IGF-1/IGFBP-3 molar ratio 0.12960.051 0.16260.068 0.16160.08 f
NS, not significant; BMI, body mass index. Values are expressed as mean 6 SD.
Each group was classified by the BMI percentile according to 2007 Korea
Growth Charts.
acontrol vs. overweight; overweight vs. obesity; control vs. obesity; respectively,
P,0.01.
bcontrol vs. overweight (P,0.01), and overweight vs. obesity (P,0.01).
ccontrol vs. overweight (P,0.01), and control vs. obesity (P,0.01).
dcontrol vs. overweight (P,0.05), and control vs. obesity (P,0.05).
eoverweight vs. obese (P,0.05).
fcontrol vs. overweight (P,0.004), and control vs. obesity (P,0.01).
doi:10.1371/journal.pone.0055084.t001
Table 2. Biochemical characteristics of subjects.
Controls OverweightObese P value
Total cholesterol (mg/dL) 145.4632.3 158.6629.0 150.3634.0 NS
HDL-cholesterol (mg/dL) 53.1613.3 53.6611.4 46.5610.6 a
Triglycerides (mg/dL) 82.9637.6 110.9647.7 103.2636.8 b
LDL-cholesterol (mg/dL) 75.9624.2 82.9623.3 84.7626.5 c
AST (IU/L) 21.8612.6 22.9610.3 26.0617.6 NS
ALT (IU/L) 11.4621.4 17.262.7 20.9620.8 a
hs-CRP (mg/dL) 0.0760.13 0.0760.13 0.1160.11 NS
Values are expressed as mean 6 SD.
acontrol vs. obesity (P,0.01), and overweight vs. obesity (P,0.01).
bcontrol vs. overweight (P,0.01), and control vs. obesity (P,0.01).
ccontrol vs. overweight (P,0.05), and control vs. obesity (P,0.05).
P values were calculated by one-way ANOVA.
doi:10.1371/journal.pone.0055084.t002
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IGFBP-3 inhibits TNF-a induced NF-kB activity in HAECs.
IGFBP-3 Suppresses MCP-1 Levels and Inhibits Monocyte
Adhesion to HAEC Monolayer
One of the consequences of chronic inflammatory state induced
by the adipokines secreted by the visceral adipose tissue is increase
in the recruitment of monocytes to cardiovascular endothelial cells,
eventually leading to plaque formation. In vitro data shows that
TNF-a-treated HAECs show increase in MCP-1 levels, whereas
IGFBP-3 abolishes TNF-a effects (Figure 5C). Since MCP-1 levels
are indicative of monocyte adhesion in cells, we performed
a monocyte adhesion experiment that showed that HAECs treated
with TNF-a lead to a two-fold increase in monocyte adhesion to
a monolayer of heart cells and infection with Ad:IGFBP-3
inhibited monocyte adhesion to HAEC cells (Figure 5D). This
confirms that IGFBP-3 inhibits a biological effect of TNF-a-
induced pro-inflammatory activity in HAECs.
IGFBP-3 Inhibits the Action of CVD Risk Factors, CRP and
High Glucose
Other factors in circulation that adversely contribute towards
CVD include insulin resistance-induced high glucose and CRP.
Increase in the mRNA levels of ICAM-1, VCAM-1 and MCP-1
was observed on addition of CRP (Figure 5E) or high glucose
(Figure 5G) and infection with IGFBP-3 significantly decreased
these levels. We also confirm that both CRP (Figure 5F) and high
glucose (Figure 5H) have a similar effect even on the protein levels
of the NF-kB downstream targets and HAEC cells infected with
Ad:IGFBP-3 reduce these levels.
IGFBP-3 Inhibits the NF-kB Pathway in an IGF-
independent Manner
In order to elucidate the underlying mechanism in the
inhibition of NF-kB pathway by IGFBP-3, and to determine if
this effect was an IGF-independent, HAECs were infected with
Ad:IGFBP-3GGG and then treated with TNF-a. Figure 6A shows
that infection with Ad: IGFBP-3GGG followed by TNF-a treatment
inhibits the mRNA levels of ICAM-1 and VCAM-1 similar to
Ad:IGFBP-3 compared to the control. This pattern was also seen
in protein expression (Figure 6B). An MCP-1 ELISA assay
determined that both Ad:IGFBP-3GGG and Ad:IGFBP-3 inhibited
TNF-a- induced MCP-1 levels (Figure 6C). Ad:IGFBP-3GGG also
inhibited monocyte adhesion to the HAECs comparable to the
effect of Ad:IGFBP-3 (Figure 6D). Furthermore, to determine if
IGFBP-3 inhibits the NF-kB pathway and its downstream targets,
through IGFBP-3R, HAECs were transfected with siRNA to
knockdown endogenous levels of IGFBP-3R (Figure 6E). Figure 6F
shows that Ad:IGFBP-3 inhibited expression of ICAM-1 by 40
percent and knockdown of IGFBP-3R negates the inhibitory effect
of IGFBP-3 on TNF-a-induced levels of downstream target of the
NF-kB pathway and restores the levels of ICAM-1.
Differential Expression of IGFBP-3 in Classically and
Alternately Activated Macrophages
In addition to adipocytes, tissue macrophages have also been
shown to be responsible for maintaining an inflammatory response
in adipose tissue [24]. Based on specific environmental stimuli,
macrophage activation can be categorized into two responses:
classical (M1) or alternative (M2) macrophages [25]. It has been
shown that obesity induces a phenotypic switch from an anti-
inflammatory M2 state to a pro-inflammatory M1 state [26]. To
determine if M1 and M2 activation affects the levels of IGFBP-3,
we used human monocytes (THP-1 cells) and differentiated them
to M1 and M2 macrophages using phorbol-12-myristate-13-
acetate (PMA)+IFN-c+LPS and PMA+IL4 respectively. We used
CCR-7 and fibronectin as markers for M1 and M2 to confirm that
our treatments did differentiate the monocytes to M1 and M2
macrophages respectively [27]. Monocytes treated with
PMA+IFN-c+LPS show higher levels of CCR7 (M1 marker) and
those treated with PMA+IL4 show increased levels of fibronectin
(M2 marker) (Figure 7A). On confirming macrophage differenti-
ation, we analyzed the mRNA and protein levels of IGFBP-3.
Figure 7B shows that M2 macrophages express approximately 5.5
fold higher levels of IGFBP-3 mRNA when compared to M1
macrophages. Further protein analysis of IGFBP-3 in the
Table 3. Insulin resistance of subjects.
Controls Overweight Obese P value
Fasting glucose (mg/dL) 75.8611.3 86.3612.5 85.367.2 a
Fasting insulin (mIU/Ml) 8.064.0 12.968.7 16.969.5 b
HOMA-IR 1.560.8 2.963.2 3.662.2 a
acontrol vs. overweight (P,0.001), and control vs. obesity (P,0.001).
bcontrol vs. overweight, overweight vs. obesity, and control vs. obesity,
respectively; P,0.001.
P values were calculated by one-way ANOVA.
doi:10.1371/journal.pone.0055084.t003
Figure 2. Effect of TNF-a on NF-kB signaling in adipocytes. (A) Differentiated adipocytes were treated with 10 ng/ml TNF-a for 0, 5, 10, 15 and
30 minutes respectively and its effect on the levels of phospho-IkBa and phospho-NF-kB was detected by western blotting. a-tubulin served as the
loading control. (B) Differentiated adipocytes were treated with different concentration (1, 10, 20 and 50 ng/ml) of TNF-a for 18 hours followed by
analysis of the mRNA levels of IRS-1, GLUT4 and adiponectin by RT-PCR. Cells were treated with 2.5 and 5.0 mM of IKK-IV inhibitor followed by
treatment with 20 ng/ml TNF-a. hb2M was used as the internal control for normalizing mRNA levels. (C) Cells were treated with 1, 5, 10 and 20 ng/ml
TNF-a for 24 hour and immunoblotted for IRS-1 and a-tubulin.
doi:10.1371/journal.pone.0055084.g002
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conditioned media reiterates that M2 macrophages express higher
levels of IGFBP-3 than M1 macrophages without any detectable
proteolyzed fragments (Figure 7C). This result suggests that in
addition to reduced levels of biologically active, intact IGFBP-3 in
circulation in obese state due to increased proteolysis, another
possible mechanism for reduced anti-inflammatory function of
IGFBP-3 in the adipose tissue could be due to reduction in the
presence of anti-inflammatory M2 macrophages resulting in
reduced expression of IGFBP-3.
Figure 3. IGFBP-3 inhibits the NF-kB pathway in primary human adipocytes in an IGF-independent manner. Effect of IGFBP-3 on IRS-1,
GLUT4, adiponectin and MCP-1 levels induced upon treatments with TNF-a (20 ng/ml) was analyzed by (A) RT-PCR (18 hours) and (B) immunoblot
analysis (36 hours). Similar experiments were performed by infecting adipocytes with mutant-Ad:IGFBP3GGG followed by treatment with TNF-a and
analyzing IRS-1, GLUT4, adiponectin and MCP-1 levels by (C) RT-PCR and (D) immunoblotting. Overexpressed IGFBP-3 levels were confirmed in these
experiments. Cells were infected with either Ad:EV (m.o.i. 500), Ad:IGFBP-3 (m.o.i. 250, 500), Ad:IGFBP-3GGG (m.o.i. 500) or IKK IV inhibitor at
a concentration of 5.0 mM. (E) Differentiated adipocytes were treated with 10, 50 and 100 nM of insulin and a glucose uptake assay was performed on
these cells. (F) The inhibitory effect of TNF-a (20 ng/ml) alone and in the presence of IKK IV inhibitor on the biological functions of insulin was
analyzed by the glucose uptake assay. (G) Human adipocytes were treated with TNF-a in the presence of insulin (100 nM) and the insulin sensitizing
effect of IGFBP-3 was analyzed by glucose uptake assay. Cells were infected with either Ad:EV or Ad:IGFBP-3 (m.o.i. 250), n = 3, in duplicate; *,
p,0.001;**, p,0.05.
doi:10.1371/journal.pone.0055084.g003
Figure 4. TNF-a activates NF-kB pathway in HAEC cells. (A) HAECs were treated with 50 ng/ml TNF-a and lysates were collected at 0, 10, 30
and 60 minutes. The cell lysates were analyzed by western blotting to observe the activation of NF-kB pathway. The figure shows phospho-IkBa and
phospho-p65 confirming activation of NF-kB pathway by TNF-a in HAEC. (B) Dose dependent increase in the mRNA levels of ICAM-1, VCAM-1 and
MCP-1 upon TNF-a treatment was analyzed by RT-PCR and GAPDH was the internal control for normalizing mRNA levels. (C) Dose dependent
increase in protein levels of ICAM-1 and VCAM-1 by immunoblotting. a-tubulin was used as the loading control. (D) The expression profile of IGFBPs
in HAECs was analyzed by RT-PCR using primers IGFBP-1 through IGFBP-6. PCR products were run on a 2% agarose gel. (E) HAEC cells were treated
with TNF-a for 48 hours and subsequently analyzed for IGFBP-3 expression in conditioned media (CM). HAECs infected with Ad:IGFBP-3 was used
a positive control.
doi:10.1371/journal.pone.0055084.g004
Impact of IGFBP-3 in Human Metabolic Syndrome
PLOS ONE | www.plosone.org 7 January 2013 | Volume 8 | Issue 1 | e55084
Discussion
Visceral fat obesity and not subcutaneous fat obesity, correlates
significantly with insulin resistance [28], hypertension [29] and
cardiac dysfunction [30]. In obesity, fat depots increase the levels
of cytokines that act in a paracrine manner further entering
circulation and resulting in a state of systemic inflammation [31].
In addition to its ability to modulate IGF availability, IGFBP-3
has also been shown to have IGF-independent effects [10].
IGFBP-3 has been shown to be associated with CVD [7], obesity
[8] and insulin resistance [32]. We and others have shown that
IGFBP-3 acts as an anti-inflammatory factor, capable of inhibiting
the NF-kB pathway [21,22,33]. Reports suggest that IGFBP-3
may act as an insulin antagonist. IGFBP-3 has been shown to
inhibit insulin-stimulated glucose uptake in adipocytes, human
omental adipose tissue, and in Sprague-Dawley rats [34,35]. It is
of note that these studies characterize IGFBP-3 function in
a normal physiological setting. However, we, in our study show
that IGFBP-3 may have a distinct function in pathologic, disease
states. Nevertheless, our data demonstrate that IGFBP-3 does not
affect insulin-induced glucose uptake under normal conditions
(Figure 3G) A recent study shows that diet-induced obese rats
Figure 5. Effect of IGFBP-3 on NF-kB pathway in HAECs: Effect of IGFBP-3 on TNF-a induced NF-kB activation in HAEC cells. HAEC
cells were infected with Ad:EV (m.o.i.100) or Ad:IGFBP-3 (m.o.i.100) for 24 hours followed by TNF-a treatment (50 ng/ml) for 24 hours and were
analyzed for mRNA and protein expression by RT-PCR and western blotting respectively. Cells were also treated with 2.5 mM IKK-IV inhibitor. Figure
(A) shows the mRNA levels for ICAM-1, VCAM-1 and MCP-1 for the treated samples and (B) shows protein expression for ICAM-1, IGFBP-3 and a-
tubulin after IGFBP-3 infection by western blotting. IGFBP-3 blot confirms expression after adenovirus infection. HAECs were treated with IKK Inhibitor
to confirm the involvement of the NF-kB pathway. The data demonstrates that IGFBP-3 inhibits TNF-a-induced NF-kB activity consequently inhibiting
the mRNA and protein levels of ICAM-1, VCAM-1 and MCP-1. (C) A similar experiment was performed with IGFBP-3 infection and TNF-a treatment and
MCP-1 levels were quantified in the CM using ELISA. n = 3, in duplicates; *, p,0.001;**, p,0.001. (D) HAEC cells were infected with Ad:IGFBP-3 and
treated with 50 ng/ml of TNF-a. At the end of the incubation, monocyte cell adhesion assay was performed. 1*105 monocytes were stained with
Calcein AM fluorescent dye and the stained cell suspension was layered over the HAEC cells. After 30 minutes of incubation non-adherent cells were
removed and only the adhered cells were analyzed by fluorescent microscopy. The figure shows a representative field of each well. The number of
adhered monocytes on the HAEC monolayer is depicted as a bar graph. n = 2, in triplicates; #, p,0.05;##, p,0.01. Effect of IGFBP-3 on CRP- and
glucose-induced NF-kB activation in HAEC cells: HAEC cells were infected with adenovirus constructs for control and IGFBP-3. Simultaneously, cells
were treated with 50 ng/ml CRP for 6 hrs or 30 mM of glucose for five days respectively. Cells were analyzed for effect on the mRNA levels (E, G) and
protein expression (F, H) respectively after CRP or glucose treatment.
doi:10.1371/journal.pone.0055084.g005
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Figure 6. IGFBP-3 inhibits NF-kB activity in an IGF-independent manner in HAECs. HAEC cells were infected with Ad:EV (m.o.i.100) or
Ad:IGFBP-3 (m.o.i.100) and Ad:IGFBP-3GGG (m.o.i. 100) followed by TNF-a treatment for 24 hours and were analyzed for mRNA (A) and protein
expression (B) by RT-PCR and western blotting respectively. (C) A similar experiment was performed with infection with Ad:EV, Ad:IGFBP-3 or
Ad:IGFBP-3GGG and TNF-a treatment and MCP-1 levels were quantified in the CM using ELISA. n = 2, in triplicates; *,#,**, p,0.001 (D) HAEC cells were
infected with Ad:IGFBP-3 or Ad:IGFB3GGG and treated with 50 ng/ml of TNF-a. At the end of the incubation period, monocyte cell adhesion assay
was performed. The numbers of adhered monocytes on the HAEC monolayer are depicted as a bar graph. n = 2 in triplicates; *, p = 0.05; #, **,
p,0.05. (E) HAEC cells were transfected with siRNA against IGFBP-3R once or two consecutive times and cells were harvested to determine the
knockdown of IGFBP-3R by western blotting. HAEC cells were transfected with either scrambled siRNA or siRNA against IGFBP-3R. (F) The cells were
then infected with Ad:EV (m.o.i.100) or Ad:IGFBP-3 (m.o.i.100) followed by TNF-a treatment for 24 hours and were analyzed for mRNA and protein
expression.
doi:10.1371/journal.pone.0055084.g006
Figure 7. Differential expression of IGFBP-3 in classically and alternately activated macrophages. PMA treated macrophages were
differentiated into M1 and M2 macrophages by treating them with IFN-c+LPS and IL-4 respectively. Figure (A) shows that M1 shows increased levels
of CCR7 (M1 marker) mRNA and Fibronectin (M2 marker) levels are higher in M2 when compared to Untreated (B) The bar graph below shows that
mRNA levels of IGFBP-3 are higher in M2 when compare to both untreated and M1 differentiated macrophages, * p,0.05. For protein analysis, equal
numbers of THP-1 cells were plated and differentiated to M1 and M2 as mentioned above and IGFBP-3 protein levels were analyzed on a western blot
by loading equal volumes of conditioned media (C).
doi:10.1371/journal.pone.0055084.g007
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show a downregulation of IGFBP-3 expression in mesenteric fat
when compared to their lean counterparts, suggesting that IGFBP-
3 may have a protective effect against obesity [36].
IGF-1 has been shown to increase insulin sensitivity and
improve glycemic control in patients with type 2 diabetes [37]. In
our data, we see that insulin resistance exists in both overweight
and obese adolescents, in spite of the levels of IGF-1 increasing in
the overweight and obese individuals. In some instances, it has
been shown that at low concentrations, IGF-1 stimulates pro-
liferation of arterial smooth muscle cells and at high concentra-
tions it inhibits smooth muscle cell proliferation. This suggests that
IGF-1 could be both a pro-atherogenic and an anti-atherogenic
factor [38] indicating that IGFBP-3 levels and its regulation on
IGF-1 may be a better indicator and marker of insulin resistance.
Proteolytic degradation of IGFBP-3 has been reported in several
catabolic conditions and proteases found in a variety of biological
fluids can degrade IGFBP-1-6 into fragments that greatly reduce
affinity for IGF-I and IGF-II, thereby increasing the concentration
of free IGF [39]. Therefore, IGFBP proteolysis directly regulates
IGF receptor signaling [40]. However, it is not known if the
proteolyzed IGFBP-3 fragments still possess intrinsic biological
functions of intact IGFBP-3 such as IGF-independent anti-
inflammatory function of IGFBP-3. It is of note that the mid
region of IGFBP-3 molecule possesses an IGFBP-3R binding
domain [13] whereas IGFBP-3 proteases appear to cleave the
IGFBP-3 mid region [41,42]. Taken together, these findings
strongly suggest that IGFBP-3 proteolysis may result in loss of
IGFBP-3R binding ability and subsequent its anti-inflammatory
function. In this study we show that IGFBP-3 proteolysis was
significantly increased in overweight as well as obesity groups
compared to normal controls by both western blotting and
protease activity assay. Its correlation with HOMA-insulin re-
sistance suggests that proteolysis of IGFBP-3 may be involved in
the pathogenesis of obesity-induced insulin resistance. Though
there are conflicting reports about the effect of obesity on IGFBP-3
proteolysis [43] it is evident that IGFBP-3 proteolysis is increased
in patients with non insulin-dependent diabetes mellitus [17]. This
further raises an interesting concept that IGFBP-3 proteolysis may
result in decrease of intact IGFBP-3 in circulation and the local
environment, thereby suppressing the intrinsic anti-inflammatory
function of IGFBP-3. Also, studies show that adipose tissue of
a lean mice have a macrophage content of less than 10% of the
total cell nuclei count, whereas obese mice present more than 50%
of macrophage content [24,44]. It has been shown that obesity
induces a phenotypic switch from an anti-inflammatory M2 state
to a pro-inflammatory M1 state [26]. On the other hand, Lumeng
et al in his study suggests that during obesity, adipose tissue
macrophages are newly recruited from monocyte precursors and
these macrophages display M1 characteristics [45]. M2 macro-
phages are known to maintain glucose tolerance, insulin sensitivity
and general adipocyte function that can prevent development of
obesity due to diet and type-2 diabetes [25,45]. In both humans
and mice, lipidystrophy has been associated with overexpression of
the M1 phenotype of macrophages [46,47]. In accordance with
the role of macrophages and the anti-inflammatory properties of
IGFBP-3, in our study we show that M2 macrophages express
higher levels of IGFBP-3 than M1, suggesting that decreased
expression of IGFBP-3 by macrophages in addition to occurrence
of IGFBP-3 proteolysis in circulation may contribute towards
obesity and insulin resistance.
Visceral adipocytes are highly responsive to TNF-a mediated
activation of NF-kB pathway [18]. Our study shows that IGFBP-3
inhibits TNF-a-induced NF-kB activity in differentiated human
adipocytes, inhibiting TNF-a-mediated deregulation of insulin
signaling in ASCs. IGFBP-3 restores the levels of IRS-1, GLUT4
and adiponectin and inhibits MCP-1 levels. NF-kB pathway has
been shown to be active in human atherosclerotic plaques and in
contrast, healthy vessels are devoid of such increased activity.
Presence of activated NF-kB pathway is observed in smooth
muscle cells, endothelial cells of atherosclerotic lesions [48] and in
the intimal cells of the coronary arteries of pigs that are fed
a hypercholesterolemic diet [49]. Many genes regulated by the
NF-kB pathway such as ICAM-1, VCAM-1, IL-8 and MCP-1
help in the recruitment of monocytes to the arterial intima. This
further leads to the migration and proliferation of smooth muscle
cells resulting in plaque formation and atherosclerosis. Since
pharmacological inhibition or genetic knockdown of adhesion
molecules, MCP-1 and TNF-a is known to retard the progression
of CVD in atherosclerotic models [50,51], in our study we
investigated and determined that in HAECs, IGFBP-3 inhibits
TNF-a-induced adhesion molecules; ICAM-1, VCAM-1 and
MCP-1, downstream of the NF-kB pathway. In addition to
inhibiting TNF-a-induced MCP-1 levels in the cells, IGFBP-3 also
prevents adhesion of monocytes to HAECs. High glucose and
CRP, that are pro-atherogenic and pro-inflammatory factors also
activate the NF-kB pathway, upregulating adhesion proteins and
recruiting monocytes to the vascular endothelium [52] and our
data shows that IGFBP-3 also inhibits CRP- and high glucose-
induced NF-kB pathway in HAECs.
Taken together, these in vitro data provide convincing evidence
that IGFBP-3 negates obesity-induced NF-kB activity in adipo-
cytes and HAECs. Our data with IGFBP-3GGG mutant further
confirms that this inhibition of the NF-kB activity occurs in an
IGF-independent manner. IGFBP-3R [13], is involved in the
inhibition of TNF-a induced NF-kB signaling cascade via the
activation of caspases and eventual apoptosis in cancer cells [11].
IGFBP-3 also inhibits NF-kB signaling in normal lung epithelial
cells via activation of the IGFBP-3R that involves activation of
caspase pathway and degradation of IkBa and p65-NF-kB
proteins, thereby inhibiting TNF-a-induced activation of NF-kB
signaling cascades and blocking the physiological manifestations of
asthma and bronchial inflammation [12]. Not surprisingly,
knockdown of endogenous IGFBP-3R in our in vitro heart cell
system negates the biological effect of IGFBP-3 and restores the
levels of ICAM-1, thereby suggesting that IGFBP-3 inhibits the
NF-kB pathway via an IGFBP-3/IGFBP-3R axis.
In conclusion, these new discoveries for the inhibitory role of
IGFBP-3 in obesity-induced insulin resistance and in the events
occurring in the early stages of atherosclerosis, set the stage for
a potential therapeutic role of IGFBP-3 in various aspects of
metabolic syndrome.
Materials and Methods
Subjects
The study consisted of 197 subjects aged 12 to 13 years old
among adolescents who visited the National Medical Center,
Korea for medical examinations. The BMI percentiles for age and
gender according to 2007 Korea Growth Charts for assessment of
obesity were utilized. At the time of study enrollment no subject
had either a chronic disease or acute illness, was taking
medications for any condition, or had a history of smoking. The
Hospital Ethnics Committee of the Severance Children’s hospital
reviewed and approved the study, and written informed consent
was obtained from guardians and study subjects.
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Anthropometric Measurements
Weight, height, BP and waist circumference were measured as
previously described [24,29].
Blood Samples Analyses
All subjects were fasted for more than 12 hours. Whole blood
samples were obtained by venipuncture. Sera were used for
biochemical and hormonal assay within 8 hours and immunoblot
assay was performed.
Biochemical and Hormonal Analyses
Level of fasting serum glucose, insulin, total cholesterol,
triglycerides, AST, ALT and HDL cholesterol were measured.
Levels of LDL cholesterol were calculated as follows: LDL-
cholesterol = total cholesterol – HDL-cholesterol–(triglyceride/5).
CRP concentrations were measured by IMMAGE assay (Beckman
Coulter, CA, USA), and fasting insulin levels were measured by
electroluminescence immunoassay. HOMA-IR was calculated as
follows: HOMA-IR= [fasting insulin (mIU/mL) x fasting glucose
(mg/dL)/18]/22.5 [25].
IGFBP-3 Protease Activity Assay
Recombinant human glycosylated IGFBP-3 was biotinylated by
Biotin-XX microscale protein labeling kit (Invitrogen). Two ul sera
and 5 ul biotinylated IGFBP-3 were incubated at 37uc for 15
minutes and subjected to WIB. IGFBP-3 protease activity was
calculated from WIB as the sum of density of the fragment bands
at 29 and 18 kDa divided by the sum of all fragments and intact
IGFBP-3 at approximately 43, 29, and 18 kDa.
ELISA Assays for IGF-I, IGFBP-3 and MCP-1 ELISA Assays
Human IGF-I ELISA (ALPCO,NH, USA), total IGFBP-3
(MEDIAGNOST, Reutlingen, Germany) and MCP-1 ELISA kits
(BD Biosciences) were purchased and assays were performed
according to manufacturer’s protocol.
Reagents
Isobutyl-methylxanthine, dexamethasone, indomethacin, insu-
lin glucose, TNF-a were purchased from Sigma, IKK inhibitor
and CRP were obtained from Calbiochem, whereas Calcein AM
from Molecular probes.
Semi Quantitative and Quantitative PCR Analysis
Total RNA was extracted and reverse transcripted, and RTQ-
PCR was performed with designed primers (Table 4) [18].
Adenoviral Constructs
Ad:IGFBP-3 and Ad:IGFBP-3GGG were generated and char-
acterized as previously described [13].
Growth, Differentiation and Maintenance of ASCs
Cells were grown to 100% confluence in the growth medium
supplemented with 10% FBS. Confluent cells were incubated in
DM for 6 days (change medium every 3 days), 1 day in MM and
then switched to DM again. This cycle was repeated for a period
of 21 days until cells were differentiated.
Macrophage Differentiation
Cells were treated with 20 ng/ml PMA for 8 hours followed by
treatment with 20 ng/ml of IFN-c and 20 ng/ml LPS for
differentiating them into M1 macrophages and 20 ng/ml IL-4
for M2 macrophages. The cells were then harvested for mRNA
analysis after 20 hours and cell lysates and conditioned media were
collected at 72 hours.
Monocyte Adhesion Assay
Equal numbers of HAEC cells were plated, followed by
adenovirus infection with Ad: EV, Ad: IGFBP-3 or Ad: IGFBP-
3GGG as required followed by TNF-a treatment with in respective
wells. A fixed number of monocytes (THP-1) were stained with
2 mM Calcein AM and the adhered monocytes were counted
using a fluorescence microscope for three representative fields.
Glucose Uptake Assay
Differentiated adipocytes were cultured in serum free low
glucose medium for 2 hours. In experiments involving adenovirus
infection, two hours after infection cells were treated with 20 ng/
ml of TNF-a. After 24 hours of incubation, cells were incubated
with or without insulin in KRPH buffer for 20 min and subjected
to glucose uptake assay.
Table 4. Primer Sequences.
Genes Primer sequence
IRS-1 fwd 59-CCTGGATTTGGTCAAGGACT-39
IRS-1 rev 59-TCATTCTGCTGTGATGTCCA-39
Glut4 fwd 59- TTATTCGACCAGCATCTTCG-39
Glut4 rev 59-AGCAGAGCCACAGTCATCAG-39
Adiponectin fwd 59-TGCTGGGAGCTGTTCTACTG-39
Adiponectin rev 59-GTTTCACCGATGTCTCCCTT-39
MCP-1 fwd 59 - ATCAATGCCCCAGTCACC - 39
MCP-1 rev 59-AGTCTTCGGAGTTTGGG-39
hb2M fwd 59- GTGCTCGCGCTACTCTCTCT-39
hb2M rev 59- TCAATGTCGGATGGATGAAA-39
IGFBP-3R fwd 59- AGACAGGAACAAGACCCGGACATT -39
IGFBP-3R rev 59- ATAGGCAGGTTCCTGCAGTCCTTT-39
ICAM-1 fwd 59-CTGCAGACAGTGACCATC-39
ICAM-1 rev 59- GTCCAGTTTCCCGGACAA-39
VCAM-1 fwd 59- AGATGGCGCCTATACCATCCGAAA -39
VCAM-1 rev 59- AGAGCACGAGAAGCTCAGGAGAAA -39
IGFBP-1 fwd 59- AGGCTCTCCATGTCACCAACATCA -39
IGFBP-1 rev 59- TGTCTCCTGTGCCTTGGCTAAACT –39
IGFBP-2 fwd 59- GCATGGCCTGTACAACCTCAAACA-39
IGFBP-2 rev 59- AGCCTCCTGCTGCTCATTGTAGA -39
IGFBP-3 fwd 59- CAGAGCACAGATACCCAGAACTTC-39
IGFBP-3 rev 59-CACATTGAGGAACTTCAGGTGATT-39
IGFBP-4 fwd 59- TGCAGAAGCACTTCGCCAAA-39
IGFBP-4, rev 59- ATGATGTAGAGGTCCTCGTGGGTG-39
IGFBP-5 fwd 59- AAAGAGCTACCGCGAGCAAGTCAA -39
IGFBP-5 rev 59- ACAAACTTGGACTGGGTCAGCTTC-39
IGFBP-6 fwd 59- AACCGCAGAGACCAACAGAGGAAT-39
IGFBP-6 rev 59- TGGTCACAATTGGGCACGTAGAGT -39
GAPDH fwd 59- CCAATAGGCGCTCACTGTTCT -39
GAPDH rev 59- GCGAACTCACCCGTTGACT -39
doi:10.1371/journal.pone.0055084.t004
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siRNA Transfection
Cells were transfected with siRNAs against IGFBP-3R (siGEN-
OME SMARTpool, Dharmacon) as described previously [23].
Statistical Analyses
To determine the statistical differences in clinical characteristics
among the three groups, we used one-way analysis of variance
(ANOVA). Pearson’s correlation coefficients were calculated to
evaluate the relationship between the degree of IGFBP-3 pro-
teolysis and clinical features. Results were considered significant
when P,0.05. All statistical analyses were performed with SAS
9.13 service pack3 (SAS Institute, Cary, NC, USA). Statistical
analyses for in vitro experiments in differentiated adipocytes and
HAECs were performed by t-test.
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